PD-L1-targeted extracellular vesicles with HSV-TK mRNA

PD-L1-targeted extracellular vesicles with HSV-TK mRNA is a preclinical-stage therapeutic candidate developed by researchers at Kyungpook National University. It consists of engineered extracellular vesicles (EVs) designed to target programmed death-ligand 1 (PD-L1) on tumor cells and deliver herpes simplex virus thymidine kinase (HSV-TK) mRNA. The EVs are engineered to express a PD-L1-targeting peptide on their surface, enabling selective internalization by PD-L1-expressing cancer cells. Once inside the recipient tumor cells, the delivered HSV-TK mRNA is translated into HSV-TK protein. In the presence of the prodrug ganciclovir (GCV), HSV-TK phosphorylates ganciclovir into its cytotoxic triphosphate form, leading to selective cell death in rapidly dividing tumor cells while sparing normal cells. This suicide gene therapy approach has demonstrated selective cytotoxicity in PD-L1-high breast cancer models (such as MDA-MB-231 cells) in preclinical studies.

Other names

PD-L1-targeted EVs carrying HSV-TK mRNAPD-L-1-targeted EVs carrying HSV-TK mRNAPD-L 1-targeted EVs carrying HSV-TK mRNAPD-L1-targeted EVs containing HSV-TK mRNAPD-L-1-targeted EVs containing HSV-TK mRNAPD-L 1-targeted EVs containing HSV-TK mRNAPD-L1-targeted extracellular vesicles carrying HSV-TK mRNAPD-L-1-targeted extracellular vesicles carrying HSV-TK mRNAPD-L 1-targeted extracellular vesicles carrying HSV-TK mRNAPD-L1-targeted extracellular vesicles containing HSV-TK mRNAPD-L-1-targeted extracellular vesicles containing HSV-TK mRNAPD-L 1-targeted extracellular vesicles containing HSV-TK mRNA